Rovensa Group Launches Rovensa Next, a New Global Biosolutions Business Unit to Shape a Sustainable Future for Agriculture
8.2.2023 13:44:00 EET | Business Wire | Press release
Faced with global challenges due to a growing population and climate change, among others, farmers need a solution to feed the planet through healthy and safe solutions. Today, Rovensa Group, a global leader of agricultural inputs for sustainable agriculture, answers that need with Rovensa Next, a new global business unit dedicated to biosolutions for agriculture that aims to give back to the Earth what the Earth gives to us. Rovensa Next makes its debut this week at Fruit Logistica Berlin (Hall 1.2, Stand B-50), the leading trade fair for the fresh fruit industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005486/en/
José Alfredo García, Co-COO Rovensa Next, Javier Calleja, incoming CEO Rovensa Group, Eric van Innis, CEO Rovensa Group and Carlos Ledó, Co-COO Rovensa Next (Photo: Business Wire)
Rovensa Next aggregates ten Rovensa Group companies, creating a holistic platform of innovative biosolutions to shape a sustainable future for agriculture and drive its bio-transformation. With this announcement, Agrichembio, Agrotecnología, Idai Nature, Microquimica, MIP Agro, OGT, Oro Agri, Rodel, SDP, and Tradecorp will become part of the new business unit, combining local technical knowledge, innovation and teams that work alongside farmers and distributors in the field to solve their sustainability challenges, with the global expertise and leadership of Rovensa Group.
Eric van Innis, Rovensa Group CEO, stated: “With this flagship project Rovensa Next, and our holistic platform of biosolutions, we are taking a strategic step forward in our goal to be a reference provider of well-balanced and sustainable solutions for agriculture. Farmers and distributors do not need a singular product or a multi-card generalist; they need specialised advisors to help them create a potent strategy that considers their local environment and challenges. Rovensa Next is our answer to our partners’ needs for sustainable crop management that leads to safe and healthy products with better quality and increased yield.”
Betting on sustainability, innovation, and technical expertise, Rovensa Next unites a global network of 30 R&D laboratories, excellence centres, fields, and greenhouses; 14 production plants; more than 84 partnerships with research centres and universities; 100 R&D and innovation specialists; and a dedicated team of more than 850 field expertsi. All of this allows Rovensa Next to be the pioneer on cutting-edge research to create more effective and environmentally friendly biosolutions that don’t compromise on performance or quality.
Carlos Ledó, Co-Chief Operating Officer of Rovensa Next, commented: “With a rising population and a rapidly changing climate, there is a clear need to transform the agricultural sector. The formation of Rovensa Next, consisting of ten brands with entrepreneurship in their DNA, gives us the right talent, know-how, expertise, and innovation to drive the necessary change in agriculture. The time is now for sustainable transformation.”
José Alfredo García, Co-Chief Operating Officer of Rovensa Next, added: “We want to be a trusted partner that helps our customers drive sustainable transformation without compromising on performance and yield output. Our unique value add is our team of field experts that work on the ground with growers to understand their needs and solve their challenges. By uniting all of our local and specialised expertise in various crops and geographical areas into one global portfolio of solutions, we aim to help facilitate, or even kickstart, the bio-transformation for customers, ultimately helping to shape an overall more sustainable future.”
With the new business unit, Rovensa Group anticipates a turnover of more than EUR 1 billion by 2025i. Today’s announcement marks the beginning of the global transition to Rovensa Next followed by local implementation across all countries from July 2023.
For more information, go to www.rovensanext.com
About Rovensa Group
Rovensa Group is a global leader in agricultural solutions for sustainable agriculture. It is a group of companies that develop, manufacture, and commercialise agricultural solutions to help farmers produce safe, healthy and nutritious food for all.
Committed to generating a positive impact through its companies, more than 4,000 employees strive each day to contribute to our mission of feeding the planet. With more than 30 Research and Development (R&D) experimental centres and laboratories across the world, we are leading the change in agriculture through science-led innovation to continuously develop pioneering agricultural inputs to preserve and enhance soil, environmental, and human health. We are providing farmers, spread over 80 countries across the globe, a complementary portfolio of solutions for bionutrition, biocontrol and crop protection to support the transition towards a more well-balanced agriculture, enabling them to grow a larger quantity and higher quality of food with fewer natural resources.
For more information, go to www.rovensa.com
- Rovensa Next figures including ten aggregated companies and the Cosmocel acquisition.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005486/en/
Contact information
For further information:
Rovensa Next
Elisa Lipperheide
Global Communication Manager
elisa.lipperheide@rovensanext.com
m. +34 687 111 148
Chelsey Rodowicz
Ogilvy PR
chelsey.rodowicz@ogilvy.com
m. +34 620 035 403
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
